January 23, 2017 | Two biomed companies, Pluristem Therapeutics Ltd. and Can-Fite BioPharma Ltd., announced financing rounds at the end of last week. Pluristem raised $15 million, after enlarging its planned offering, while Can-Fite raised $5 million. In May, Pluristem, an Israeli company developing placenta-based therapy products, announced that it was awarded a NIS 12.7 million (approx. $3.3 million) grant from the Israel Innovation Authority (previously the Office of the Chief Scientist ‘OCS’) of the Israeli Ministry of Economy & Industry. The grant will support Clinical trials and R&D activities for calendar year 2016. Pluristem was founded in 2001 by Shai Meretzki. Can-Fite is an Israeli biopharmaceutical company founded in 1994 with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors

Ashdod Port Investing In Startups As Part Of Innovation Strategy

Facebook comments